Dogwood Therapeutics reported net income of -$12.80M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.33M | 0.33M | 0.33M | 0.33M | 0.37M | 0.44M | 0.73M | 0.73M | 0.77M | 0.77M | 0.77M | 0.92M | 1.11M | 1.03M | 1.44M | 1.91M | 2.29M | 4.98M | 33.40M | 33.63M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 2.96M | 2.92M | 2.77M | 2.41M | 1.62M | 1.27M | 0.50M | 0.56M | 0.37M | 0.30M | 0.34M | 0.34M | 0.54M | 2.32M | 2.44M | 2.57M | 14.52M | 2.34M | 2.67M | 3.25M | ||||||
| Selling, General & AdministrativeSG&A | 1.15M | 1.27M | 1.19M | 1.27M | 0.97M | 0.82M | 1.06M | 0.92M | 0.90M | 0.84M | 0.97M | 0.73M | 1.77M | 5.23M | 1.99M | 1.35M | 1.29M | 1.47M | 2.41M | 1.63M | ||||||
| Other Operating ExpensesOther Opex | 9.19M | |||||||||||||||||||||||||
| Operating ExpensesOpex | 4.11M | 4.19M | 3.96M | 3.67M | 2.59M | 2.09M | 1.56M | 1.48M | 1.27M | 1.14M | 1.31M | 1.07M | 2.30M | 7.54M | 4.43M | 3.92M | 15.81M | 3.81M | 5.08M | 14.06M | ||||||
| Operating IncomeOp. Inc | -4.11M | -4.19M | -3.96M | -3.67M | -2.59M | -2.09M | -1.56M | -1.48M | -1.27M | -1.14M | -1.31M | -1.07M | -2.30M | -7.54M | -4.43M | -3.92M | -15.81M | -3.81M | -5.08M | -14.06M | ||||||
| EBIT | -4.11M | -4.19M | -3.96M | -3.67M | -2.59M | -2.09M | -1.56M | -1.48M | -1.27M | -1.14M | -1.31M | -1.07M | -2.30M | -7.54M | -4.43M | -3.92M | -15.81M | -3.81M | -5.08M | -14.06M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.04M | 0.04M | 0.03M | 0.02M | 0.02M | 0.02M | -0.16M | -0.15M | 0.11M | 0.08M | 0.05M | 0.08M | 0.07M | |||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.00M | -0.32M | 906.00 | 0.00M | 0.02M | 0.05M | 0.04M | 0.04M | 0.04M | 0.03M | 0.02M | 0.02M | 0.02M | -0.19M | -6.30M | 0.12M | 0.06M | 0.09M | 0.05M | |||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -4.11M | -4.51M | -3.96M | -3.67M | -2.58M | -2.04M | -1.52M | -1.44M | -1.24M | -1.10M | -1.29M | -1.05M | -2.28M | -7.73M | -10.73M | -3.81M | -15.75M | -3.75M | -4.99M | -14.01M | ||||||
| Profit After TaxPAT | -4.11M | -4.51M | -3.96M | -3.67M | -2.58M | -2.04M | -1.52M | -1.44M | -1.24M | -1.10M | -1.29M | -1.05M | -2.28M | -11.59M | -10.92M | -3.81M | -17.11M | -3.78M | -4.99M | -12.80M | ||||||
| Income from Non-Controlling InterestsInc. Minority | 0.02M | 0.02M | ||||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -4.11M | -4.51M | -3.96M | -3.67M | -2.58M | -2.04M | -1.52M | -1.44M | -1.24M | -1.10M | -1.29M | -1.05M | -2.28M | -7.73M | -10.73M | -3.81M | -15.75M | -3.75M | -4.99M | -14.01M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -4.11M | -4.51M | -3.96M | -3.67M | -2.58M | -2.04M | -1.52M | -1.44M | -1.24M | -1.10M | -1.29M | -1.05M | -2.28M | -7.73M | -10.73M | -3.81M | -15.75M | -3.75M | -4.99M | -14.01M | ||||||
| Income towards Parent CompanyParent Net Inc | -4.11M | -4.51M | -3.96M | -3.67M | -2.58M | -2.04M | -1.52M | -1.44M | -1.24M | -1.10M | -1.29M | -1.05M | -2.28M | -7.73M | -10.73M | -3.81M | -15.75M | -3.75M | -4.99M | -14.01M | ||||||
| Net Income towards Common StockholdersNet Income | -4.11M | -4.51M | -3.96M | -3.67M | -2.58M | -2.04M | -1.52M | -1.44M | -1.24M | -1.10M | -1.29M | -1.05M | -2.28M | -8.24M | -12.18M | -3.81M | -15.74M | -3.78M | -4.99M | -11.53M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -12.33 | -13.54 | -11.89 | -11.01 | -7.00 | -4.62 | -2.07 | -1.96 | -1.62 | -1.47 | -1.68 | -1.15 | -2.05 | -8.02 | -8.45 | -1.99 | -8.20 | -0.76 | -0.15 | -0.34 | ||||||
| EPS (Diluted) | -12.33 | -13.54 | -11.89 | -11.01 | -7.00 | -4.62 | -2.07 | -1.96 | -1.62 | -1.47 | -1.68 | -1.15 | -2.05 | -8.02 | -8.45 | -1.99 | -8.20 | -0.76 | -0.15 | -0.34 | ||||||
| Shares Outstanding | 0.33M | 0.33M | 0.33M | 0.33M | 0.37M | 0.44M | 0.73M | 0.74M | 0.76M | 0.75M | 0.77M | 0.92M | 1.11M | 1.03M | 1.44M | 1.91M | 1.92M | 4.98M | 33.54M | 34.13M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.33M | 0.33M | 0.33M | 0.33M | 0.37M | 0.44M | 0.73M | 0.74M | 0.76M | 0.75M | 0.77M | 0.92M | 1.11M | 1.03M | 1.44M | 1.91M | 1.92M | 4.98M | 33.54M | 34.13M | ||||||
| EBITDA | -4.11M | -4.19M | -3.96M | -3.67M | -2.59M | -2.09M | -1.56M | -1.48M | -1.27M | -1.14M | -1.31M | -1.07M | -2.30M | -7.54M | -4.43M | -3.92M | -15.81M | -3.81M | -5.08M | -14.06M |